HomeIndustriesHealthcareEvolus CEO on Medical Aesthetics Growth & New Products

Evolus CEO on Medical Aesthetics Growth & New Products

Evolus is a performance beauty company focused exclusively on cash-pay aesthetics. Its flagship product, Jeuveau®, is the fastest-growing neurotoxin in the U.S., capturing 13% market share in just five years. Evolus is now expanding its portfolio with Evolysse™, a line of unique injectable hyaluronic acid dermal fillers expected to launch in Q2 2025, marking the first major innovation in the filler market in over a decade.

Morning Trade Live

30 Jan 2025

SHARE

ON AIR
4:30 pm
Market On Close
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
education
5:00 am
Liz Ann Live
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Market Overtime
REPLAY
8:00 am
Market Overtime
REPLAY
8:30 am
Market On Close
REPLAY
education
10:00 am
Schwab 2026 Outlook
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Liz Ann Live
REPLAY
1:30 pm
The Wrap
REPLAY
3:00 pm
Market Overtime
REPLAY
4:00 pm
Market Overtime
REPLAY
ON AIR
4:30 pm
Market On Close
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Fast Market
REPLAY
8:00 pm
Next Gen Investing
REPLAY
education
9:00 pm
Liz Ann Live
REPLAY
9:30 pm
The Wrap
REPLAY
11:00 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor